Paganuzzi M, Onetto M, Marroni P, Barone D, Conio M, Aste H, Pugliese V
Division of Clinical Pathology, National Institute for Cancer Research, Genova, Italy.
Cancer. 1988 May 15;61(10):2100-8. doi: 10.1002/1097-0142(19880515)61:10<2100::aid-cncr2820611028>3.0.co;2-z.
Serum concentrations of the CA 19-9 and CA 50 antigens were determined in 129 patients with malignant and benign biliary and pancreatic diseases. Values for the two markers were highly correlated (P less than 0.001). The concentrations of CA 19-9 and CA 50 were positive in 84.6% and 80.7% of patients with pancreatic cancer, respectively. The overall specificity of CA 19-9 (92.4%) was slightly higher than that of CA 50 (88.5%). The sensitivity of CA 50 (91.3%) was greater than that of CA 19-9 (73.9%) in patients with diseases of the biliary tract. Elevated concentrations of CA 19-9 (12.9%) and CA 50 (35.2%) were also found in a number of cases with benign disease, especially in patients with obstructive jaundice. These data suggest that both CA 19-9 and CA 50 can be useful markers of pancreatic cancer in nonjaundiced patients. The joint use of the two markers does not yield a better diagnostic resolution than the use of either one alone.
对129例患有恶性和良性胆道及胰腺疾病的患者测定了血清CA 19-9和CA 50抗原浓度。两种标志物的值高度相关（P小于0.001）。胰腺癌患者中CA 19-9和CA 50浓度的阳性率分别为84.6%和80.7%。CA 19-9的总体特异性（92.4%）略高于CA 50（88.5%）。在胆道疾病患者中，CA 50的敏感性（91.3%）高于CA 19-9（73.9%）。在一些良性疾病病例中，尤其是梗阻性黄疸患者中，也发现CA 19-9（12.9%）和CA 50（35.2%）浓度升高。这些数据表明，CA 19-9和CA 50在非黄疸患者中均可作为胰腺癌的有用标志物。联合使用这两种标志物并不比单独使用其中任何一种产生更好的诊断分辨率。
